Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Just a bit from the licensing agreement! Hehehe.

$Monte Rosa Therapeutics (GLUE.US)$ Novartis has agreed to pay Monte Rosa $150 million up front. Monte Rosa is eligible to receive up to $2.1 billion in development, regulatory, and sales milestones, beginning upon initiation of Phase 2 studies, as well as tiered royalties on ex-U.S. net sales. Monte Rosa will co-fund any Phase 3 clinical development and will share any profits and losses associated with the manufacturing and commercialization of MRT-6160 in the U.S.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
Translate
Report
1400 Views
Comment
Sign in to post a comment